Publication Database

Proteomic analysis of extracellular vesicles derived from canine mammary tumour cell lines identifies protein signatures specific for disease state (2024)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Gutierrez-Riquelme, Tania (WE 3)

Karkossa, Isabel

Schubert, Kristin

Liebscher, Gudrun

Packeiser, Eva-Maria

Nolte, Ingo

von Bergen, Martin

Murua Escobar, Hugo

Aguilera-Rojas, Matias

Einspanier, Ralf (WE 3)

Stein, Torsten (WE 3)

Quelle

BMC veterinary research

Bandzählung: 20

Heftzählung: 1

Seiten: 488

ISSN: 1746-6148

Sprache

Englisch

Verweise

URL (Volltext): https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-024-04331-1

DOI: 10.1186/s12917-024-04331-1

Pubmed: 39462388

Kontakt

Institut für Veterinär-Biochemie

Oertzenweg 19 b
14163 Berlin
+49 30 838 62225
biochemie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Background

Canine mammary tumours (CMT) are among the most common types of tumours in female dogs. Diagnosis currently requires invasive tissue biopsies and histological analysis. Tumour cells shed extracellular vesicles (EVs) containing RNAs and proteins with potential for liquid biopsy diagnostics. We aimed to identify CMT subtype-specific proteome profiles by comparing the proteomes of EVs isolated from epithelial cell lines derived from morphologically normal canine mammary tissue, adenomas, and carcinomas.

Methods

Whole-cell protein lysates (WCLs) and EV-lysates were obtained from five canine mammary cell lines: MTH53A (non-neoplastic); ZMTH3 (adenoma); MTH52C (simple carcinoma); 1305, DT1406TB (complex carcinoma); and their proteins identified by LC-MS/MS analyses. Gene Ontology analysis was performed on differentially abundant proteins from each group to identify up- and down-regulated biological processes. To establish CMT subtype-specific proteomic profiles, weighted gene correlation network analysis (WGCNA) was carried out.

Results

WCL and EVs displayed distinct protein abundance signatures while still showing the same increase in adhesion, migration, and motility-related proteins in carcinoma-derived cell lines, and of RNA processing and RNA splicing factors in the adenoma cell line. WGCNA identified CMT stage-specific co-abundant EV proteins, allowing the identification of adenoma and carcinoma EV signatures not seen in WCLs.

Conclusions

EVs from CMT cell lines exhibit distinct protein profiles reflecting malignancy state, allowing us to identify potential biomarkers for canine mammary carcinomas, such as biglycan. Our dataset could therefore potentially serve as a basis for the development of a less invasive clinical diagnostic tool for the characterisation of CMT.